Artelo Biosciences, Inc. announced the commencement of an underwritten public offering of its common stock and/or pre-funded warrants.
The offering is subject to market conditions, with no assurance on completion or the actual size/terms of the offering.
R.F. Lafferty & Co., Inc. is the sole book-running manager for the offering.
Offering Details
Underwritten public offering of common stock and/or pre-funded warrants.
Book-Running Manager
R.F. Lafferty & Co., Inc. is managing the offering.
Regulatory Compliance
Offering made in compliance with a 'shelf' registration statement on Form S-3.
- Artelo Biosciences is taking steps to raise capital through this public offering.
- The company aims to utilize the raised funds for further development and commercialization of therapeutics.
The underwritten public offering signifies a strategic move by Artelo Biosciences to support its pipeline development and address significant unmet needs in various medical conditions.